The main objective of WP4 is to assess the validity and usefulness of omics signatures identified and validated in WPs 1, 2 and 3 for improved identification and risk stratification of patients with EHBP and stratification of patients with PHT.
The specific objectives of the WP are:
- To compare the diagnostic accuracy of omics-based signatures for identifying patients with EHBP compared with standard procedures.
- To determine the prognostic value of the omics signatures by assessing their relationship with outcome measures after one year follow-up, including BP, BP related target organ damage (TOD) and QoL.
- To assess the potential usefulness of the omics signatures for stratification of patients with PHT.
- To relate the use of omics signatures to the social impact of hypertension, including QoL, degree of psychosocial burden, patients’ lives and economic effects.